We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Alkermes PLC | NASDAQ:ALKS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.19 | 0.80% | 24.05 | 22.69 | 25.69 | 24.48 | 23.92 | 24.14 | 1,347,148 | 01:00:00 |
DUBLIN, June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 3:20 p.m. PT (6:20 p.m. ET/11:20 p.m. BST) from Rancho Palos Verdes, Calif. The audio portion of the fireside chat may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Contact:
Jennifer Zibuda
Investor Relations
+1 781 609 6129
View original content with multimedia:http://www.prnewswire.com/news-releases/alkermes-to-present-at-goldman-sachs-39th-annual-global-healthcare-conference-300661094.html
SOURCE Alkermes plc
Copyright 2018 PR Newswire
1 Year Alkermes Chart |
1 Month Alkermes Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions